Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
|Articles|November 15, 2021
Pharmacy Clinical Pearl of the Day: Liver Cancer
Author(s)Saro Arakelians, PharmD
Risk factors for liver cancer include chronic infection with hepatitis B or hepatitis C virus, cirrhosis, diabetes, and non-alcoholic fatty liver disease.
Advertisement
Clinical Pearl of the Day: Liver Cancer
Liver cancer begins in the cells of the liver.
Insight:
- The most common type of liver cancer is hepatocellular carcinoma, which begins in the main type of liver cell (hepatocyte).
- Some of the symptoms include weight loss, appetite loss, upper abdominal pain, vomiting, general weakness, abdominal swelling, white and chalky stool.
- Risk factors include chronic infection with hepatitis B or hepatitis C virus, cirrhosis, inherited liver diseases, diabetes, non-alcoholic fatty liver disease, and alcohol consumption.
- Diagnosis includes blood test, imaging tests, and removing a sample of the liver for biopsy.
- Treatment includes surgery, targeted drug therapy, immunotherapy, chemotherapy, and supportive care.
- Some of the chemotherapy drugs include gemcitabine (Gemzar), oxaliplatin (Eloxatin), cisplatin, doxorubicin (pegylated liposomal doxorubicin), 5-fluorouracil (5-FU), capecitabine (Xeloda), and mitoxantrone (Novantrone).
- Sources:
Advertisement
Related to this article
As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar it and the potential risks.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
2
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
5